About
Zehna Therapeutics develops non-bactericidal small molecule inhibitors targeting specific gut microbial enzymes to reduce systemic TMAO levels, aiming to treat chronic cardiometabolic diseases with a lead indication in chronic kidney disease.
Explore Zehna Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.